Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC6 known ✓ | Q9UBN7 | 1/20 | 0.47 |
| ▸ | GAA known ✓ | P10253 | 1/20 | 0.42 |
| ▸ | MAOB known ✓ | P27338 | 3/20 | 0.42 |
| ▸ | SRC known ✓ | P12931 | 1/20 | 0.40 |
| ▸ | MAOA known ✓ | P21397 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 3/20 | 0.47 |
| ▸ | GRM4 | Q14833 | 3/20 | 0.47 |
| ▸ | MAPT | P10636 | 5/20 | 0.44 |
| ▸ | RAB9A | P51151 | 2/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | IDO1 | P14902 | 1/20 | 0.43 |
| ▸ | TDO2 | P48775 | 1/20 | 0.43 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.39 |
| ▸ | P2RY4 | P51582 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4133738 | 0.98 | NPC1 (0.48) | NPC1GRM4HDAC6MAPTRAB9A | |
| Bromide SCHEMBL20984091 | 0.96 | NPC1 (0.47) | NPC1GRM4HDAC6MAPTRAB9A | |
| Sulfuric Acid SCHEMBL20984581 | 0.88 | GRM4 (0.48) | NPC1GRM4HDAC6MAPTRAB9A | |
| Oxalic Acid SCHEMBL28374158 | 0.88 | MAPT (0.54) | NPC1GRM4HDAC6MAPTRAB9A | |
| Phosphoric Acid SCHEMBL28378845 | 0.88 | GRM4 (0.51) | NPC1GRM4HDAC6MAPTRAB9A | |
| Nitric Acid SCHEMBL28377488 | 0.85 | GRM4 (0.46) | NPC1GRM4HDAC6MAPTRAB9A | |
| Hydrochloric Acid SCHEMBL4073968 | 0.85 | NPC1 (0.55) | NPC1GRM4MAPTRAB9APOLB | |
| SCHEMBL5809000 | 0.82 | MAPT (0.54) | NPC1GRM4MAPTRAB9APOLB | |
| Hydrochloric Acid SCHEMBL7408286 | 0.82 | MAPT (0.49) | NPC1MAPTRAB9AKDM4ETDP1 | |
| Bromide SCHEMBL20984140 | 0.81 | MAPT (0.53) | NPC1GRM4MAPTRAB9APOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11040938-B2 | Continuous flow process for the synthesis of phenylhydrazine salts and substituted phenylhydrazine salts | SHANGHAI HYBRID-CHEM TECHNOLOGIES (CN) | 2021-06-22 | — | — | US | claimed |
| CN-107663161-B | Continuous flow synthesis process of phenylhydrazine salt and substituted phenylhydrazine salt | 上海惠和化德生物科技有限公司 | 2020-04-10 | — | — | CN | claimed |
| US-20190152896-A1 | Continuous Flow Process For the Synthesis of Phenylhydrazine Salts and Substituted Phenylhydrazine Salts | SHANGHAI HYBRID-CHEM TECHNOLOGIES (CN) | 2019-05-23 | — | — | US | claimed |
| US-11759454-B2 | Diazole lactams | CHEMOCENTRYX, INC. (US) | 2023-09-19 | — | — | US | disclosed |
| US-11040938-B2 | Continuous flow process for the synthesis of phenylhydrazine salts and substituted phenylhydrazine salts | SHANGHAI HYBRID-CHEM TECHNOLOGIES (CN) | 2021-06-22 | — | — | US | disclosed |
| US-20210093613-A1 | DIAZOLE LACTAMS | CHEMOCENTRYX, INC. | 2021-04-01 | — | — | US | disclosed |
| US-10744118-B2 | Diazole lactams | CHEMOCENTRYX, INC. (US) | 2020-08-18 | — | — | US | disclosed |
| CN-107663161-B | Continuous flow synthesis process of phenylhydrazine salt and substituted phenylhydrazine salt | 上海惠和化德生物科技有限公司 | 2020-04-10 | — | — | CN | disclosed |
| US-20190152896-A1 | Continuous Flow Process For the Synthesis of Phenylhydrazine Salts and Substituted Phenylhydrazine Salts | SHANGHAI HYBRID-CHEM TECHNOLOGIES (CN) | 2019-05-23 | — | — | US | disclosed |
| EP-2928474-B1 | DIAZOLE LACTAMS | CHEMOCENTRYX INC (US) | 2018-11-14 | — | — | EP | disclosed |
| US-20160303084-A1 | DIAZOLE LACTAMS | CHEMOCENTRYX, INC. | 2016-10-20 | — | — | US | disclosed |
| US-9328116-B2 | Diazole lactams | CHEMOCENTRYX, INC. (US) | 2016-05-03 | — | — | US | disclosed |
| EP-2928474-A1 | DIAZOLE LACTAMS | ChemoCentryx, Inc. (US) | 2015-10-14 | — | — | EP | disclosed |
| CN-104902898-A | Diazole lactams | CHEMOCENTRYX INC | 2015-09-09 | — | — | CN | disclosed |
| US-20140171420-A1 | DIAZOLE LACTAMS | CHEMOCENTRYX, INC. (US) | 2014-06-19 | — | — | US | disclosed |
| WO-2014089495-A1 | DIAZOLE LACTAMS | CHEMOCENTRYX, INC. (US) | 2014-06-12 | — | — | WO | disclosed |
| EP-2234972-A1 | N-ARYL-N-PIPERIDIN-4-YL-PROPIONAMIDE DERIVATIVES AND THEIR USE AS OPIOID RECEPTOR LIGANDS | NeuroSearch A/S (DK) | 2010-10-06 | — | — | EP | disclosed |
| WO-2009077584-A1 | N-ARYL-N-PIPERIDIN-4-YL-PROPIONAMIDE DERIVATIVES AND THEIR USE AS OPIOID RECEPTOR LIGANDS | NEUROSEARCH A/S (DK) | 2009-06-25 | — | — | WO | disclosed |
| WO-2000018741-A2 | PYRAZOLE COMPOUNDS AS COX-2 INHIBITORS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2000-04-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160303084-A1 | DIAZOLE LACTAMS | CCR1, CCRL2, CCR4 | HDAC6 1468/4885GAA 2803/4885MAOB 4791/4885 |
| US-20210093613-A1 | DIAZOLE LACTAMS | CCR1, CCRL2, CCR4 | HDAC6 1468/4885GAA 2803/4885MAOB 4791/4885 |
| US-20140171420-A1 | DIAZOLE LACTAMS | CCR1, CCRL2, CCR4 | HDAC6 1468/4885GAA 2803/4885MAOB 4791/4885 |
| US-11040938-B2 | Continuous flow process for the synthesis of phenylhydrazine salts and substituted phenylhydrazine salts | HPD, TYR, PDK2 | HDAC6 1827/4885GAA 237/4885MAOB 220/4885 |
| US-10744118-B2 | Diazole lactams | CCR1, CCRL2, CCR4 | HDAC6 1468/4885GAA 2803/4885MAOB 4791/4885 |
| US-11759454-B2 | Diazole lactams | CCR1, CCRL2, CCR4 | HDAC6 1468/4885GAA 2803/4885MAOB 4791/4885 |
| US-20190152896-A1 | Continuous Flow Process For the Synthesis of Phenylhydrazine Salts and Substituted Phenylhydrazine Salts | HPD, TYR, PDK2 | HDAC6 1827/4885GAA 237/4885MAOB 220/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.